Triple-negative breast cancer vaccine shows good response in first clinical trial of patients
A new breast cancer vaccine sparked an immune response in three out of four patients during its first human safety trial — with no serious side effects reported. The Cleveland Clinic study targeted triple-negative breast cancer, an aggressive subtype that resists most standard treatments and disproportionately affects younger women and Black women. The vaccine works by training the immune system to recognize a lactation protein found in most TNBC tumors but absent in healthy adult tissue, giving immune cells a clear target. Next come larger trials testing whether it can prevent recurrence and even attack active tumors. It’s an early but hopeful signal in the growing field of cancer immunotherapy, where teaching the body to find cancer itself is reshaping what treatment can look like.
